For breast cancer patients, tamoxifen or gonadotropin-releasing hormone analogs are selected, while in postmenopausal women, tamoxifen and aromatase inhibitors (AIs) are indicated [20].These medications can potentially cause atrophy of the genitourinary tract in women with abundant ER [21]. This evidence concerns the gene ESR1 and breast carcinoma.